Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


QUEENSLAND UNIVERSITY OF TECHNOLOGY

Brisbane, Queensland, AU

QUEENSLAND UNIVERSITY OF TECHNOLOGY Patent applications
Patent application numberTitlePublished
20110269716ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE - The invention relates to antioxidant substituted isoindoline nitroxide compounds and their use in methods of treating or preventing diseases or disorders related to oxidative stress, methods of reducing oxidative stress and methods of protecting a subject from oxidative stress upon exposure to ionising radiation. Pharmaceutical compositions comprising the antioxidant compounds are also described.11-03-2011
20110172163Novel Protease Inhibitors - The invention relates to KLK protease inhibitors. In particular, the invention is directed to KLK4 protease inhibitors and their uses in the treatment of a cancer, such as prostate cancer.07-14-2011
20110119782CONSTRUCT CAPABLE OF RELEASE IN CLOSED CIRCULAR FORM FROM A LARGER NUCLEOTIDE SEQUENCE PERMITTING SITE SPECIFIC EXPRESSION AND/OR DEVELOPMENTALLY REGULATED EXPRESSION OF SELECTED GENETIC SEQUENCES - The present invention relates generally to constructs and in particular genetic constructs comprising polynucleotide sequences capable of release in covalently closed, circular form from a larger nucleotide sequence such as, but not limited to, a genome of a eukaryotic cell. Preferably, once released, a polynucleotide sequence is reconstituted in a form which permits expression of the polynucleotide sequence. In one embodiment, the reconstituted polynucleotide sequence comprises a coding sequence with all or part of an extraneous nucleotide such as, but not limited to, an intronic sequence or other splice signal inserted therein. Expression and in particular transcription of the coding sequence involves splicing out the extraneous sequence. The release and circularization is generally in response to a stimulus such as a protein-mediated stimulus. More particularly, the protein is a viral or prokaryotic or eukaryotic derived protein or developmentally and/or tissue specific regulated protein.05-19-2011
20100281566TRANSCRIPTIONAL CONTROL ELEMENT, CHIMERIC CONSRUCTS AND USES THEREFOR - This invention discloses a constitutive promoter for expression of foreign or endogenous coding sequences in plants, including dicotyledonous and monocotyledonous plants. The invention also discloses a chimeric nucleic acid construct comprising the promoter of the invention operably linked to a foreign or endogenous polynucleotide that codes for a protein of interest or a transcript capable of modulating expression of a target gene. The invention further discloses transformed plant cells, as well as differentiated plants and plant parts, containing the construct. Methods for diagnosis and treatment of viral infections, especially badnaviral infections, are also disclosed.11-04-2010
20100276955TREATMENT OF RAILWAY WHEELS - A method of treating a steel railway wheels to form a required distribution of compressive residual stress in the rim. In general terms the wheel heated and then quenched from the plate towards the rim. The wheel is first heated to form austenite throughout the plate and rim portions. The wheel is then cooled to form bainite/martensite in the plate portion. The wheel is cooled to form bainite/martensite in an inner portion of the rim. The wheel is cooled to form bainite/martensite in an outer portion of the rim.11-04-2010
20100172860WOUND REPAIR COMPOSITION AND METHOD - The invention provides a dressing composition comprising a bisphosphonate matrix metalloproteinase (MMP) inhibitor covalently bound to a polymer wherein, when the dressing is contacted with a wound, substantially all of the bisphosphonate remains with the dressing composition and is unable to enter the wound tissue. The invention also provides for a method of treatment of a wound by contacting a dressing composition comprising a covalently bound MMP inhibitor with the wound fluid to thereby selectively inhibit one or more MMP's in the wound fluid without inhibiting those in the wound tissue.07-08-2010
20090311303BIODEGRADABLE IMPLANTS FOR BONE FUSION AND COMPOSITIONS THEREFOR - A biodegradable copolymer network, which is particularly suited for use in applications such as interbody implants for bone fusion, is provided. The biodegradable copolymer network of the present invention is biodegradable yet provides sufficient mechanical strength for use in procedures such as spinal fusion. Also provided are methods of producing said biodegradable copolymer network, methods of delivery of biologically active substances, implants comprising said biodegradable copolymer network and methods of administering bioactive and in particular, osteoinductive, substances.12-17-2009
20090291432Genetic profiles associated with the 957C>T polymorphism in the DRD2 gene - The present invention relates to a method for profiling an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention identifies a genetic profile associated with the 957C>T polymorphysm within the dopamine receptor D2 (DRD2), indicating a predisposition to schizophrenia and other neurological diseases.11-26-2009
20090141235Control of Myopia Using Contact Lenses - Devices and methods for controlling myopia are provided. The devices and methods relate to the inventors discovery of the relationship between near work, the forces applied to the eye by the eyelids and myopia. The devices include a contact lens comprising a region that disperses force applied to the eye by an eyelid. The devices also include a device designed by measuring first wavefront aberrations of an eye before pre-near work and measuring second measured wavefront aberrations of the eye post-near work. The methods include a method for controlling myopia including identifying optical changes associated with near work and correcting the optical changes with an optical device.06-04-2009
20090076742ESTIMATION OF WHEEL RAIL INTERACTION FORCES - A method of estimating contact forces between the wheels of a railway wagon and a rail track, for use in determining information such as the likelihood of derailment. Accelerations of the body of the wagon are measured using motion sensors located at suitable points on the body. Forces on the side frames of the wagon are calculated based on the accelerations of the body and predetermined parameters of the body. Forces on the wheels of the wagon are calculated based on the accelerations of the body and predetermined parameters of the body. The contact forces between the wheels and the rails are then calculated based on the forces calculated for the side frames and the wheels. The calculations are carried out using an inverse model of the wagon system. Equipment which implements the method is also described.03-19-2009
20090075827DIAGNOSTIC METHODS AND AGENTS - The present invention relates generally to a method and agents for profiling or stratifying an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention utilizes genetic means to profile or stratify individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state. The present invention enables the identification of individuals at risk of these disorders thus affording the opportunity for early intervention. In addition, the subject invention allows the prediction of drug or other treatment response and adverse reactions.03-19-2009
20090028891Chlamydia Antigens and Uses Thereof - The invention provides protein and nucleic acid sequences of 01-29-2009
20080299067Functionalised Siloxanes for Scar Tissue Treatment - A novel composition for use in treating a wound, burn or other skin condition comprises one or more compounds of formula (I), wherein: m = 0-6, n = 6-100, Q, R and R′ may be independently selected from, C1-5 alkyl, OU, UOCH2CH3, CH2CH3, UOCH3, OH, O(CH2)y(OU)yCH3, (OCH2CH2)yOU, (OCH2CH2)yOH, UOH, UOU′, UCO2U′, CO2U, UCO2COU, CO2H, UCO2H, COX, UCOX, UCO2 R′, CO2COU, Aryl, ArylU, ArylUU, ArylUU′U″, NH2, UNH2, NHU, NUU′, NO2, UNO2, UCONH2, CONH2, UCONHU′, CONHU, UCONU′U″, CONU′U″, halogen, PO4H3, PO4H3-z, PO4H3-zU (z = 0, 1, 2 or 3), PU3, P U′U″U′″SH, SO2 and SO3H; wherein U, U′, U″ and U′″ may be independently selected from any alkyl, alkenyl or alkynyl group where the number of carbon atoms is between 1 and 31; wherein X=halogen; wherein y=1-100; provided that Q, R and R′ can not all be C1 alkyl; and wherein the compound of formula (I) is present in an amount of at least 1% of the composition.12-04-2008

Patent applications by QUEENSLAND UNIVERSITY OF TECHNOLOGY